



HAL
open science

Awareness dimensions and associated factors in Alzheimer's disease

Jean-Pierre Jacus, V. Voltzenlogel, A. Mayelle, P. Antoine, C.-V.
Cuervo-Lombard

► **To cite this version:**

Jean-Pierre Jacus, V. Voltzenlogel, A. Mayelle, P. Antoine, C.-V. Cuervo-Lombard. Awareness dimensions and associated factors in Alzheimer's disease. *Revue Neurologique*, 2022, 178 (4), pp.363-369. 10.1016/j.neurol.2021.05.011 . hal-04336241

HAL Id: hal-04336241

<https://hal.science/hal-04336241v1>

Submitted on 11 Dec 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Awareness dimensions and associated factors in Alzheimer's disease**

2 Jacus J-P ^{1,2}, Voltzenlogel V ³, Mayelle A ², Antoine P ^{2,4}, Cuervo-Lombard C-V ³.

3 ¹ CH des vallées de l'Ariège, Consultations mémoire, Foix, France.

4 ² Univ. Lille, CNRS, CHU Lille, UMR 9193 - SCALab - Sciences Cognitives et Sciences
5 Affectives, F-59000 Lille, France.

6 ³ CERPPS, Centre d'Etudes et de Recherche en Psychopathologie et Psychologie de la Santé,
7 EA7411, Université Jean Jaurès, Toulouse, France.

8 ⁴ LabEx DISTALZ - Development of Innovative Strategies for a Transdisciplinary approach
9 to ALZheimer's disease, F-59000 Lille, France.

10 **Corresponding author:** Jean-Pierre Jacus, CH des vallées de l'Ariège, Foix, France. Tel: +
11 33 (0) 6 85 07 64 72 – Fax: + 33 (0) 5 61 03 31 75
12 Mail: jeanpierrej@chi-val-ariege.fr

1 **ABSTRACT**

2 **Objectives** – We recently reported the major role depression and apathy in awareness among
3 Alzheimer patients, using the stage of the disease as an exposure factor and exploring
4 different assessment methods. Using the same patient data, we aimed here to explore the
5 different dimensions of awareness assessed by different sub-scales in awareness scales.

6 **Method** – Sixty-one Alzheimer patients were examined using four awareness scales relating
7 to three assessment methods: (a) *patient-caregiver discrepancy*; (b) *clinical rating*; and (c)
8 *prediction of performance discrepancy*. Global cognition, executive functioning, autonomy,
9 depression and apathy were also assessed. Multivariate logistic models were performed using
10 disease stage as an exposure factor for awareness scales and sub-scales. Correlations across
11 the different factors and patient and caregiver awareness ratings were computed.

12 **Results** – The *patient-caregiver discrepancy* and *clinical rating* methods (a, b) both identified
13 the factors associated with awareness in the overall scales and the sub-scales as being
14 depression and/or apathy. Depression correlated with patient self-ratings while apathy
15 correlated with caregiver ratings. The *prediction of performance discrepancy* method (c)
16 identified different factors in the overall scale, executive factors in three sub-scales involving
17 executive domains and the memory factor in a sub-scale involving the mnemonic domain.

18 **Discussion** – The awareness scales using a referential based on a human rating (a, b) suggest
19 that awareness is unidimensional, with depression impacting self-reports and apathy
20 influencing caregiver/clinical reports. Scales based on a test rating (c) appear to be more
21 closely associated with the dimensions assessed. This highlights the role of the reference
22 system for awareness assessment in Alzheimer’s disease.

23 **KEY WORDS** – Alzheimer’s disease, Apathy, Awareness assessment method, Awareness
24 dimensions, Depression.

1 1 INTRODUCTION

2 Awareness disturbances are core features in Alzheimer's disease (AD) prematurely affecting
3 patient autonomy and causing early placement in structured living environments ^[1]. This
4 symptomatology is heterogeneous and various terms to refer to different conceptualizations
5 have been used to describe it ^[2]. Anosognosia was the first term used. It involves cognitive
6 conceptualizations suggesting a main role of metacognition in this phenomenon ^[3]. Denial is
7 more often used in psychoanalytical conceptualizations, in reference to the unconscious
8 refusal to acknowledge a too painful reality ^[4]. Insight, especially in its broader form, is a
9 psychiatric viewpoint involving judgments and the nature of patients' consciousness of their
10 disorders, in particular delusions and hallucinations. In its narrower form ("*insight into*
11 *dementia*"), awareness is conceptualized as the basic perception of impairments ^[5]. Other
12 conceptualizations have been proposed, but it is known that none of them are able to explain
13 the heterogeneity of awareness disturbances in AD ^[6]. This is why Clare and colleagues ^[6]
14 developed a bio-psychosocial model suggesting that awareness disturbances relate to a self-
15 adjustment as resulting from biological, psychological and social changes with the progress of
16 the disease. Subsequently phenomenological models have considered the disease experience
17 expressed by the patient in order to take the heterogeneity of awareness into account by way
18 of different mechanisms or processes (comparison between past and present, metacognition,
19 etc.), domains (communication, memory, autonomy, etc.) and modes of expression (denial,
20 bewilderment, causal attribution, etc.) ^[7].

21 Except for bio-psychosocial and phenomenological approaches, awareness in AD is
22 classically assessed using three methods ^[8]. The *patient-caregiver discrepancy* method, using
23 the caregiver ratings as the reference by subtracting the patient ratings from them. The scales
24 using this method explore different domains or dimensions of awareness, such as cognitive or
25 behavioural disturbances. The *clinical rating* method use a structured interview with the

1 patient concerning different domains of impairment in which the clinician rating is used as the
2 reference. The *prediction of performance discrepancy* method in which the scores obtained on
3 the test used are the reference to be compared to the predictions. The domains of awareness
4 explored are those of the test used.

5 These three methods mainly focus on awareness dimensions, which are presented as the first
6 aspect to consider to understand patients with impaired awareness of their disorder ^[8].
7 However, using these methods, many studies have reported heterogeneous results, attributed
8 mainly to the different assessment methods, domains of awareness and disease stages studied
9 ^[5]. Alongside, awareness seems to be associated with disease stage ^[9]. In a previous study ^[1],
10 we recently suggested a model of awareness in AD using disease severity as an exposure
11 factor (*risk factor of impaired awareness*) and integrating these three main assessment
12 methods. The results showed that greater awareness was associated with greater depression
13 and lower apathy for all the scales relating to the *patient-caregiver discrepancy* and *clinical*
14 *rating* methods. Greater awareness was associated with more heterogeneous factors (apathy
15 and especially *cognition*) in the *prediction of performance discrepancy* method.

16 Nevertheless, these results did not take into account the role of the different dimensions of
17 awareness (i.e. the different sub-scales or dimensions included in each scale used). Because
18 awareness is heterogeneous, one disturbance can be recognized while another can be
19 misunderstood by the patient, and thus it is relevant to take into account their impact in daily
20 living. Therefore, using the same patient data as in our previous study ^[1], our objective was
21 here to evaluate the role of these dimensions and their associated factors.

22 Considering the heterogeneity of awareness disturbances in AD ^[1, 5, 8], we hypothesized that in
23 addition to the factors (apathy-depression in particular) usually associated with global
24 awareness scores ^[1, 9-10], there would be specific factors associated with the different
25 awareness dimensions (i.e. a cognitive awareness sub-scale will be associated with cognitive

1 functions, a subtest on awareness of activity of daily living abilities will be associated with
2 autonomy in daily living, and so on).

3 **2 MATERIALS AND METHOD**

4 2.1 Participants

5 Sixty-one Alzheimer patients (mean age=81.3; % female=50.8) recruited from a memory
6 clinic and diagnosed following the National Institute for Aging and the Alzheimer's
7 Association working group recommendations ^[11] were included in this study. They
8 constituted the patient group of our previous study ^[1] that also included healthy controls.

9 2.2 Evaluation tools

10 AD patients were assessed using four awareness scales related to the three main assessment
11 methods presented above ^[1, 9].

12 (a) For the patient-caregiver discrepancy method:

- 13 – The *Patient Competency Rating Scale* – PCRS ^[12] including the sub-scales: "*Activities of*
14 *Daily living (ADL)*", "*Cognition*", "*Interpersonal Relations*" and "*Emotions*". The PCRS
15 asks the participant and a relative the same 30 questions on the participant's ability to
16 perform various daily living activities. Levels of awareness on the overall scale and each
17 sub-scale are assessed by subtracting the participant's rating from the relative's rating.
18 Positive scores indicate greater awareness.
- 19 – The *Anosognosia Questionnaire for Dementia* – A-QD ^[13] including "*Cognitive*" and
20 "*Behavioral disturbances*" sub-scales, designed on the same principle as the PCRS.
21 Awareness is scored in a similar manner to the PCRS, but negative scores indicate greater
22 awareness.

1 (b) For the clinical rating method, we used the *Self-Consciousness Scale in AD – SCSAD* ^[14],
 2 a structured patient interview involving seven dimensions of self-consciousness: "*Identity*",
 3 "*Cognitive disturbances*", "*Affective state*", "*Bodily representation*", "*Prospective memory*",
 4 "*Introspection abilities*" and "*Moral judgments*". Higher scores indicate greater awareness.

5 (c) For the *prediction of performance discrepancy* method, we used the *Multidimensional*
 6 *Isomorphic Simple Awareness Assessment – MISAware* ^[15] which requires participants to
 7 predict their neuropsychological performance on the *Dementia Rating Scale – DRS* ^[16]. The
 8 self-ratings are then compared to those obtained on the DRS, which includes five sub-scales:
 9 "*Attention*", "*Initiation*", "*Conceptualization*" relating to executive functioning,
 10 "*Construction*" relating to visuo-spatial functioning, and "*Memory*" relating to mnesic
 11 functioning. Lower scores indicate greater awareness.

12 AD patients also completed the *Mini Mental State Examination – MMSE* ^[17-18] and the
 13 *Frontal Assessment Battery – FAB* ^[19] for cognitive performances. We used the *Instrumental*
 14 *Activities of Daily Living scale – IADL* ^[20], scored by a relative, to assess autonomy. Most
 15 patients (n=55) were also evaluated using the *Free and Cued Recall Test – FCRT* ^[21],
 16 assessing episodic memory. For all tasks, higher scores indicate better abilities.

17 Levels of depression and apathy, known to be involved in awareness in AD, were assessed ^[9].
 18 We used the *Geriatric Depression Scale – GDS* (completed by the patient) ^[22], in which
 19 higher scores indicate greater depression, and the *Apathy Evaluation Scale – AES* ^[23]
 20 (completed by a relative: AES_{Relative} and the clinician: AES_{Clinician}), in which lower scores
 21 indicate greater apathy.

22 2.3 Statistical analyses

23 The statistical analyses were carried out using R software (version 4.0.2) (generalhoslem,
 24 Hmisc, and questionr packages). In order to identify the factors associated with the different

1 awareness scales or sub-scales and disease stage, we performed a backward manual regression
2 for each of them, using the following variable selection method ^[1-24]. To perform the
3 regressions there must be no missing data. The MMSE score was used as the exposure factor
4 determining the stage of AD ^[1, 18] and was always maintained in the model. Demographics
5 (age, educational level in years and gender), autonomy (IADL), executive functioning (FAB),
6 apathy (AES) and depression (GDS) were univariately tested with each of the four global
7 measures of awareness and for each of their sub-scales or dimensions. The cut-off was set at
8 $p < 0.25$ for this preliminary model in order to avoid excluding future significant variables.
9 Each interaction between the exposure factor (MMSE) and the variables retained in the
10 preliminary model was univariately tested with the dependent variable. The cut-off was also
11 set at $p < 0.25$. Once the preliminary model was established with the selected interactions, the
12 backward process began, removing one by one the non-significant interactions ($p < 0.05$),
13 beginning with those having the highest p-values. If an interaction was found to be
14 significant, therefore the factor interacting with the exposure factor was maintained in the
15 model even if it was non-significant. The same process was performed with the non-
16 significant main factors ($p < 0.05$). When removal of a main factor impacted at least 15% of
17 the exposure factor estimate (relative variation: $\frac{\text{adjusted estimate} - \text{crude estimate}}{\text{adjusted estimate}}$), the factor
18 was considered as a potential confounder and was therefore maintained in the model, given
19 that this relative variation is significant when it falls between 10 and 20% ^[1]. The analysis was
20 discontinued when there were no remaining significant factors. Confounding factors and the
21 exposure factor (MMSE) remained in the final model. Because some sub-scales did not
22 comply with the validity conditions for linear models, we used logistic multivariate models,
23 setting a cut-off at the median value of the sample for each dependent variable^a (overall

^a Given that a logistic model is by definition binary.

1 awareness scales and sub-scales). Finally, we ascertained each model by the Hosmer and
2 Lemeshow test (χ^2 non-significant)^b.

3 Because the conditions of parametric correlations (Pearson) were not fulfilled, we calculated
4 non-parametric correlations between the available variables and predictions on the MISAware
5 as well as self and caregiver's awareness reports, in order to have a better understanding of
6 the logistic models.

7 **3 RESULTS**

8 We reported in Table 1 the demographic, cognitive, behavioural and awareness patient data.

9 3.1 Logistic models for the overall awareness scales and sub-scales

10 These models are presented in Table 2.

11 Because logistic models were used in the present study while we used linear models in our
12 previous study ^[1], we checked that there were globally the same associations with the overall
13 awareness scales.

14 While the total PCRS scores evidenced associations with the GDS and AES_{Relative} in our
15 previous study using a linear model ^[1], the total score was here associated with the same
16 factors and the MMSE using a logistic model (GDS: OR=0.52, CI95%=0.32–0.75, $p=0.002$;
17 AES_{Relative}: OR=0.89, CI95%=0.81–0.96, $p=0.005$; MMSE: OR=1.26, CI95%=1.02–1.60,
18 $p=0.004$). All the PCRS sub-scales were associated with the GDS and/or the AES_{Relative}-
19 Clinician. However, the "*Interpersonal Relations*" logistic model did not comply with the
20 Hosmer and Lemeshow test ($\chi^2=16.48$, $p=0.03$).

21 While the total A-QD score evidenced associations with the GDS and AES_{Relative} in our
22 previous study using a linear model ^[1], the total score remained associated with the same

^b The Hosmer–Lemeshow test is a statistical test for goodness-of-fit for logistic regression models.

1 factors using a logistic model. Nevertheless, only the "Cognition" sub-scale was associated
2 with the GDS and the AES_{Relative}. For the "Behavioral disturbances" sub-scale, there was
3 merely a significant trend for both GDS and AES_{Relative} (OR=0.76, CI95%=0.55–0.99,
4 $p=0.059$; OR=0.94, CI95%=0.87–1.00, $p=0.066$ respectively).

5 Only three of the seven dimensions in the SCSAD proved discriminant and were useable:
6 "Cognitive disturbances", "Introspection abilities" and "Moral judgments". The others
7 showed no variance and always reached the top scores.

8 While the total SCSAD score evidenced associations with the GDS and AES_{Clinician} in our
9 previous study using a linear model ^[1], the total score was here only associated with the
10 AES_{Relative} and the AES_{Clinician} using a logistic model (AES_{Relative}: OR=0.89, CI95%=0.80–
11 0.97, $p=0.019$; AES_{Clinician}: OR=0.87, CI95%=0.74–0.99, $p=0.050$). The three available
12 dimensions were associated with the GDS and/or the AES_{Relative-Clinician} and also with
13 demographic variables.

14 While the total MISAware evidenced associations with the MMSE, AES_{Relative} and FAB in our
15 previous study using a linear model ^[1], the total score was here significantly associated with
16 the MMSE, AES_{Relative} and gender (female) using a logistic model (MMSE: OR=0.68,
17 CI95%=0.51–0.85, $p=0.002$; AES_{Relative}: OR=0.84, CI95%=0.72–0.94, $p=0.003$; gender
18 (female): OR=0.52, CI95%=1.19–2.85, $p=0.038$). The "Attention", "Initiation" and
19 "Conceptualization" sub-scales were associated solely with the FAB, except for the
20 "Attention" sub-scale, also significantly associated with age. The analysis failed to show
21 significant factors associated with the "Construction" and "Memory" sub-scale scores.
22 Nevertheless, in a complementary analysis introducing the FCRT (administered only to 55
23 patients), we observed that the "Memory" sub-scale showed a significant association with total
24 recall ($p=0.020$), the GDS ($p=0.040$) and interactions between GDS and MMSE ($p=0.033$).

1 3.2 Non-parametric correlations (Table 3)

2 For non-parametric correlations across the available factors, including self/relative reports for
3 PCRS, A-QD and MISAware predicted scores, the significance cut-off was set at $p < 0.01$
4 because there were twenty-five (25) correlations. The predicted MISAware scores correlated
5 with the MMSE and AES_{Clinician} ($\rho = 0.46, p = 0.0002$; $\rho = 0.35, p = 0.0062$ respectively). Relative
6 reports for the PCRS and for A-QD correlated with IADL ($\rho = 0.46, p = 0.0002$; $\rho = -0.41,$
7 $p = 0.0010$ respectively), AES_{Relative} ($\rho = 0.61, p < 0.0001$; $\rho = -0.66, p < 0.0001$ respectively) and
8 AES_{Clinician} ($\rho = 0.33, p = 0.0099$; $\rho = -0.33, p = 0.0087$ respectively). Finally, self-reports for the
9 PCRS and A-QD correlated solely with the GDS ($\rho = -0.58, p < 0.0001$; $\rho = 0.45, p = 0.0003$
10 respectively).

11 4 DISCUSSION

12 Our present results show that the linear models used in our previous study ^[1] and the
13 subsequent logistic models found the same overall associations with only minor differences.

14 Concerning both the *patient-caregiver discrepancy* and the *clinical rating* methods, our
15 results suggest that, whatever the domain assessed, greater awareness is associated with
16 greater depression and/or lower apathy. **Contrary** to our hypothesis relating to the role of
17 specific factors associated with the domains assessed, cognitive awareness sub-scales did not
18 show any associations with cognitive functions, such as the MMSE or FAB scores, when
19 using these methods.

20 Concerning the *prediction of performance discrepancy*, the total MISAware scores did not
21 evidence the same associations as three of its sub-scales (MMSE, gender and apathy versus
22 executive functioning measured with the FAB only for "Attention", "Initiation" and
23 "Conceptualization"). Two sub-scales showed no associations, but after introducing an
24 additional explanatory variable assessing episodic memory measured by the FCRT,

1 associations with the "Memory" sub-scale were observed. This suggests that awareness could
2 be associated with specific domains assessed by different sub-scales, highlighting the
3 importance of awareness dimensions when using this method.

4 Our results still suggest a distinction between a referential based on a test rating and another
5 based on a human rating (clinician or relative). This was suggested in our previous study [1]
6 and seems to be congruent here, using only patient data for overall awareness scales and sub-
7 scales. The referential based on a test rating seems relatively congruent with cognitive models
8 focusing on the role of metacognition, because awareness domains proved to be associated
9 with specific factors assessed by the DRS. Thus, the MISAware sub-scales "Attention",
10 "Initiation" and "Conceptualization" mainly involving executive functioning were associated
11 with the FAB which also relates to executive functions. The MISAware "Memory" sub-scale
12 was associated with the FCRT assessing episodic memory. Finally, the MISAware
13 "Construction" sub-scale relating to the visuo-spatial domain failed to show any significant
14 association, perhaps because we did not introduce a visuo-spatial test in the logistic model.
15 The referential based on a human rating yields results congruent with the conceptualization of
16 awareness proposed by Marková [5], in its narrower form ("insight into dementia"). This
17 author considers this narrower form as determined only by the patient's perception of
18 impairment. Therefore, insight into dementia is unidimensional, so that the only dimension of
19 awareness is that of the impairment itself, whatever the domain concerned.

20 Depression scores correlated only with self-reports, which could be understood as an
21 underestimation of their abilities by patients with greater depression. This interpretation is
22 congruent with research reporting that depression, anxiety, and certain personality traits
23 influence subjective cognitive complaints [25]. Autonomy and apathy scored by relative and
24 clinician correlated with relative reports. Autonomy and apathy scored by a relative lacked
25 relevance because the person scoring was also the one who scored in the relative awareness

1 report. However, the correlation between relative reports and apathy scored by the clinician
2 was more relevant. Various studies have reported associations between poorer awareness and
3 greater apathy [1, 9, 26]. There is a growing body of evidence that apathy and impaired
4 awareness are common manifestations in AD. Clinically, Starkstein et al. [26] reported that
5 anosognosia predicts apathy in AD. From a neuro-anatomical viewpoint, both apathy and
6 impaired awareness involve the anterior cingulate cortex [26], although it has been reported
7 that awareness deficit, but not apathy, correlates with atrophy in the dorsal anterior cingulate
8 cortex [27]. Finally, apathy is consensually divided into three dimensions: loss of interest, loss
9 of initiative and affective blunting [28], which could influence relative ratings and clinical
10 ratings alike, explaining why apathy was also associated with the SCSAD in the different
11 logistic models. Apathy scored by the clinician was also correlated with patient predictions
12 using the MISAware. This could explain the associations between the apathy scores and the
13 total MISAware score, because an overestimation of abilities could be associated with apathy.
14 Indeed, an apathetic patient would have a lack of sensitivity towards his deficits and
15 inabilities. Finally, one possible relevant question is whether impaired awareness is a main
16 component of apathy.

17 Several limitations should be underlined concerning this research. The sample size could be
18 criticised given to our statistical strategy derived from epidemiological methods. There was
19 collinearity between the factors entered into the model, and the model did not reflect all the
20 variables known to be involved in awareness. Some sub-scales in awareness scales such as the
21 SCSAD include a few items yielding unsustainable results. In addition, several models used
22 for the awareness sub-scales did not previously suit linear modelling, requiring logistic
23 models, leading to a loss of information probably explaining the slight differences between
24 linear and logistic models for the global scales (see 3.1). This is why we kept exactly the same
25 patient data as that used in our previous study [1], to confirm the same overall associations,

1 and to test the impact of these associations across the different domains of awareness
2 assessed. Nevertheless, we did not anticipate at the time of our previous study ^[1] that we
3 would need to explore the role of awareness dimensions. Therefore, in the present study, some
4 scales exploring behavioural disturbances, such as the *NeuroPsychiatric Inventory* ^[29], which
5 could be associated with awareness in this domain, are lacking.

6 In conclusion, it appears that the role of awareness dimensions varies with the method used.
7 The *patient-caregiver discrepancy* and *clinical rating* methods do not evidence the role of
8 awareness dimensions, while they are supposed to be focused on them ^[8]. In contrast, in the
9 *prediction-performance discrepancy* method, awareness appears strongly associated with the
10 domains assessed (as specific factors). Consequently, this method seems to be the most
11 relevant to assess awareness dimensions in clinical practice. Nevertheless, these basic
12 approaches are either too restricted to depression and apathy or mainly dependent on the
13 domains assessed to obtain a broad understanding of awareness experienced by patients with
14 AD in daily living. Thus, a phenomenological perspective proposing a person-centred
15 approach would be more relevant to capture broader phenomena of awareness in AD ^[7-8].

16 **The authors have no conflict of interest to report.**

17 **Acknowledgments:** The authors would like to thank and Mrs Angela VERDIER and Sarah
18 LEYSHON for their linguistic and scientific assistance.

19 **5 REFERENCES**

20 [1] Jacus JP, Mayelle A, Voltzenlogel V, Cuervo-Lombard C-V, Antoine P. Modelling
21 awareness in Alzheimer's disease, *J Alzheimers Dis* 2020; 76(1): 89-95. doi:10.3233/JAD-
22 200017

- 1 [2] Jacus JP, Dupont MP, Hérades Y, Pélix C, Large H, Baud M. Awareness Disorders in
2 Alzheimer's Disease and in Mild Cognitive Impairment. *Encéphale* 2014; 40(2): 180-7. doi:
3 10.1016/j.encep.2013.10.003.
- 4 [3] McGlynn SM, Schacter DL. Unawareness of deficits in neuropsychological syndromes. *J*
5 *Clin Exp Neuropsychol* 1989; 11(2): 143-205. doi:10.1080/01688638908400882
- 6 [4] Weinstein EA, Friedand RP. Wagner EE. Denial/unawareness of impairment and
7 symbolic behaviour in Alzheimer's disease. *Neuropsychiatry Neuropsychol Neurol* 1994; 7:
8 176-84.
- 9 [5] Marková Y. Insight in psychiatry. Cambridge: Cambridge, UK University Press; 2005.
- 10 [6] Clare L. The construction of awareness in early-stage Alzheimer's disease: A review of
11 concepts and models. *Br J Clin Psychol* 2004; 43: 155-75. doi:
12 10.1348/014466504323088033
- 13 [7] Mayelle A, El Haj M, Antoine P. Awareness of Self and Disease Assessment:
14 Development and Validation of a Subjective Measure in People with Alzheimer's Disease. *J*
15 *Alzheimers Dis* 2019; 71: 841-50. doi: 10.3233/JAD-190371
- 16 [8] Mayelle A, El Haj M, Antoine P. "What" and "How": A New Perspective for
17 Understanding Unawareness in Alzheimer's Disease Through a Combination of Two
18 Perspectives. *Am J Alzheimers Dis Other Demen* 2020; 35: 1-9. doi:
19 10.1177/1533317520925333
- 20 [9] Starkstein SE. Anosognosia in Alzheimer's disease: Diagnosis, frequency, mechanism and
21 clinical correlates. *Cortex* 2014; 61: 64-73. doi: 10.1016/j.cortex.2014.07.019

- 1 [10] Azocar I, Livingston G, Huntley J. The Association Between Impaired Awareness and
2 Depression, Anxiety, and Apathy in Mild to Moderate Alzheimer's Disease: A Systematic
3 Review. *Front Psychiatry* 2021; 12: 633081. doi: 10.3389/fpsyt.2021.633081
- 4 [11] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CRJr, Kawa CH, et al. The
5 diagnosis of dementia due to Alzheimer's disease: recommendations from the National
6 Institute on Aging and the Alzheimer's Association workgroup on diagnostic guidelines for
7 Alzheimer's disease. *Alzheimers Dement* 2011; 7(3): 263-9. doi: 10.1016/j.jalz.2011.03.005
- 8 [12] Prigatano GP, Fordyce DJ. Cognitive dysfunction and psycho-social adjustment after
9 brain injury. In: Prigatano GP, editor. *Neuropsychological rehabilitation after brain injury*,
10 Baltimore: The Johns Hopkins University Press; 1989: p. 96-118.
- 11 [13] Starkstein SE, Jorge R, Mizrahi R, Robinson RG. A diagnostic formulation for
12 anosognosia in Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 2006; 77: 719-25. doi:
13 10.1136/jnnp.2005.085373
- 14 [14] Gil R, Arroyo-Anllo M, Ingrand D, Gil M, Neau JP, Ormon C, Bonnaud V. Self-
15 consciousness and Alzheimer's disease. *Acta Neurol Scand* 2001; 104: 296-300. doi:
16 10.1034/j.1600-0404.2001.00280.x
- 17 [15] Antoine P, Nandrino JL, Billiet C. Awareness of deficits in Alzheimer's disease patients:
18 Analysis of performance prediction discrepancies. *Psychiatry Clin Neurosci* 2013; 67: 237-
19 44. doi: 10.1111/pcn.12050
- 20 [16] Mattis S. Mental status examination for organic mental syndrome in the elderly patient.
21 In: Bellack L, Karusu TB, editors. *Geriatric Psychiatry*. New York: Grune & Stratton, 1989;
22 p. 77-121.

- 1 [17] Folstein MF, Folstein SE, McHugh PR. Mini Mental State. A practical method for
2 grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975; 12: 189-98. doi:
3 10.1016/0022-3956(75)90026-6
- 4 [18] Hugonot-Diener L. The Mini Mental Status Examination or MMSE consensual version
5 of GRECO. *Rev Geriatr* 2007; 32(3): 225-9.
- 6 [19] Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: A frontal assessment battery at
7 bedside. *Neurology* 2000; 55: 1621-6. doi:0.1212/wnl.55.11.1621
- 8 [20] Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental
9 activities of daily living. *Gerontologist* 1969; 9(3): 179-86.
- 10 [21] Ergis AM, Van der Linden M, Deweir B. L'exploration des troubles de la mémoire
11 épisodique dans la maladie d'Alzheimer débutante au moyen d'une épreuve de rappel indicé.
12 *Revue de Neuropsychologie* 1994; 4: 47-68.
- 13 [22] Clément JP, Nassif RF, Léger JM, Marchan F. Development and contribution to the
14 validation of a brief French version of the Yesavage Geriatric Depression Scale. *Encephale*
15 1997; 23(2): 91-9.
- 16 [23] Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the apathy
17 evaluation scale. *Psychiatry Res* 1991; 38: 143-62. doi: 10.1016/0165-1781(91)90040-v
- 18 [24] Heinze G, Wallisch C, Dunkler D. Variable selection – A review and recommendations
19 for the practicing statistician. *Biom J* 2017; 60: 431-49.
- 20 [25] Ryu SY, Kim A, Kim S, Park KW, Park KH, Youn YC, et al. Self-and informant-
21 reported cognitive functioning and awareness in subjective cognitive decline, mild cognitive

1 impairment, and very mild Alzheimer disease. *Int J Geriatr Psychiatry* 2020; 35(1): 91-8. doi:
2 10.1002/gps.5224

3 [26] Starkstein SE, Brockman S, Bruce D, Petracca G. Anosognosia Is a Significant Predictor
4 of Apathy in Alzheimer's Disease. *J Neuropsychiatry Clin Neurosci* 2010; 22: 378-83.
5 doi:10.1176/jnp.2010.22.4.378.

6 [27] Guerrier L, Le Men J, Gane A, Planton M, Salabert S, Payoux P, et al. Involvement of
7 the Cingulate Cortex in Anosognosia: A Multimodal Neuroimaging Study in Alzheimer's
8 Disease Patients. *J Alzheimers Dis* 2018; 65: 443-53. doi:10.3233/JAD-180324

9 [28] Mulin E, Leone E, Dujardin K, Delliaux M, Leentjens A, Nobili F, et al. Diagnostic
10 Criteria for Apathy in Clinical Practice. *Int J Geriatr Psychiatry* 2011; 26: 158-65.
11 doi:10.1002/gps.2508.

12 [29] Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia
13 patient. *Neurology* 1997; 48: S10-6. doi: 10.1212/wnl.48.5_suppl_6.10s.

14

1 **Table 1: Demographic, cognitive, behavioural and awareness patient data.**

| | Variables | Patients (n=61) |
|-------------------|-------------------------------------|------------------------|
| | (lowest – best scores) ¹ | Mean ($\pm \sigma$) |
| Demographic | Age (years) | 81.26 (\pm 6.32) |
| | Education (years) | 9.84 (\pm 2.69) |
| | Gender (% female) | 50.82 |
| Cognitive | IADL (0 – 8) | 5.97 (\pm 1.49) |
| | MMSE (0 – 30) | 22.9 (\pm 3.62) |
| | BREF (0 – 18) | 13.54 (\pm 2.78) |
| Behavioral / mood | GDS (0 – 15) | 4.05 (\pm 2.42) |
| | AES relative (72 – 0) | 46.08 (\pm 10.01) |
| | AES clinician (72 – 0) | 49.43 (\pm 6.84) |
| Awareness | PCRS (-130 – 130) | -11.44 (\pm 19.61) |
| | AQ-D (90 – -90) | 5.59 (\pm 13.05) |
| | MISAware (103 – 0) | 8.61 (\pm 13.32) |
| | Self Consciousness (0 – 28) | 23.25 (\pm 1.96) |

2 ¹ Lowest score indicates lowest cognitive performances, lowest level of depression, lowest level of apathy and
3 lowest level of awareness (most impaired awareness).

4 **AES**: Apathy Evaluation Scale (scored by a relative or the clinician); **A-QD**: Anosognosia Questionnaire for
5 Dementia; **FAB**: Frontal Assessment Battery; **GDS**: Geriatric Depression Scale; **MISAware**: Multidimensional
6 Isomorphic Simple Awareness Assessment; **MMSE**: Mini Mental State Evaluation; **PCRS**: Patient Competency
7 Rating Scale; **Self Consciousness**: Self-Consciousness scale in Alzheimer's disease.

1 **Table 2: Associated factors with awareness scales and sub-scales**

| Awareness scales / sub-scales | | GDS | AES _{Relative} | AES _{Clinician} | Others | |
|-----------------------------------|--------------------------------------|--------------------------|--------------------------|------------------------------|-----------------------------|--|
| Referential based on human rating | Total PCRS | OR=0.52, <i>p</i> =0.002 | OR=0.89, <i>p</i> =0.005 | | MMSE (<i>p</i> =0.004) | |
| | <i>PCRS Activity of Daily Living</i> | OR=0.59, <i>p</i> =0.010 | OR=0.87, <i>p</i> =0.001 | | | |
| | <i>PCRS Cognition</i> | OR=0.57, <i>p</i> =0.003 | | OR=0.87, <i>p</i> =0.010 | | |
| | <i>PCRS Int. Relations</i> | | OR=0.90, <i>p</i> =0.005 | | | |
| | <i>PCRS Emotion</i> | | OR=0.90, <i>p</i> =0.002 | | | |
| | ----- | | | | | |
| | Total A-QD | OR=0.57, <i>p</i> =0.006 | OR=0.87, <i>p</i> =0.003 | | | |
| | <i>A-QD Cognition</i> | OR=0.60, <i>p</i> =0.011 | OR=0.88, <i>p</i> =0.003 | | | |
| | <i>A-QD Behav. Disturb.</i> | OR=0.76, <i>p</i> =0.059 | OR=0.94, <i>p</i> =0.066 | | | |
| | ----- | | | | | |
| Total SCSAD | | OR=0.89, <i>p</i> =0.019 | OR=0.87, <i>p</i> =0.050 | | | |
| <i>SCSAD Cog. Disturb</i> | OR=0.74, <i>p</i> =0.047 | OR=0.94, <i>p</i> =0.049 | | | | |
| <i>SCSAD Introspection</i> | | | OR=0.84, <i>p</i> =0.007 | Education (<i>p</i> =0.008) | | |
| <i>SCSAD Moral Judgments</i> | | | OR=0.82, <i>p</i> =0.004 | Age (<i>p</i> =0.023) | | |
| Awareness scales / sub-scales | | MMSE | AES _{Relative} | FAB | Others | |
| Ref. based on test rating | Total MISAware | OR=0.68 <i>p</i> =0.002 | OR=0.84, <i>p</i> =0.003 | | Gender ♀ (<i>p</i> =0.038) | |
| | <i>Attention</i> | | | OR=0.52, <i>p</i> =0.013 | Age (<i>p</i> =0.005) | |
| | <i>Initiation</i> | | | OR=0.63, <i>p</i> =0.006 | | |
| | <i>Concept</i> | | | OR=0.74, <i>p</i> =0.038 | | |
| | <i>Construction</i> | | | | | |
| | <i>Memory</i> | | | | | |

2 AES: Apathy Evaluation Scale (scored by a relative or the clinician); **A-QD**: Anosognosia Questionnaire for
 3 Dementia; **FAB**: Frontal Assessment Battery; **GDS**: Geriatric Depression Scale; **MISAware**: Multidimensional
 4 Isomorphic Simple Awareness Assessment; **MMSE**: Mini Mental State Evaluation; **PCRS**: Patient Competency
 5 Rating Scale; **SCSAD**: Self-Consciousness scale in Alzheimer’s disease.

1 **Table 3: Correlations across demographic, cognitive (including autonomy), behavioural**
 2 **(including mood) variables, self/relative awareness reports and predictions**

| | MMSE | IADL _a | GDS | AES _{Relative} | AES _{Clinician} |
|----------------------|---|--|---|---|--|
| PCRS patient rating | $\rho=-0.03, p=0.79$ | $\rho=0.15, p=0.25$ | $\rho=-0.58, p<0.0001$ | $\rho=0.06, p=0.64$ | $\rho=-0.01, p=0.92$ |
| PCRS relative rating | $\rho=0.09, p=0.47$ | $\rho=0.46, p=0.0002$ | $\rho=0.04, p=0.77$ | $\rho=0.61, p<0.0001$ | $\rho=0.33, p=0.0099$ |
| A-QD patient rating | $\rho=0.12, p=0.37$ | $\rho=0.00, p=0.99$ | $\rho=0.45, p=0.0003$ | $\rho=0.10, p=0.44$ | $\rho=0.03, p=0.85$ |
| A-QD relative rating | $\rho=-0.26, p=0.04$ | $\rho=-0.41, p=0.0010$ | $\rho=0.10, p=0.45$ | $\rho=-0.66, p<0.0001$ | $\rho=-0.33, p=0.0087$ |
| MISAware predictions | $\rho=0.46, p=0.0002$ | $\rho=0.27, p=0.03$ | $\rho=-0.08, p=0.55$ | $\rho=0.22, p=0.09$ | $\rho=0.35, p=0.0062$ |

3 ρ : Non-parametric Spearman's correlation; _a: Scored by relative; **Significant correlations ($p<0.01$)**

4